Literature DB >> 4873186

A clinical trial of mithramycin in the treatment of advanced malignant disease.

M Baum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4873186      PMCID: PMC2008246          DOI: 10.1038/bjc.1968.25

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  4 in total

1.  Clinical trial with mithramycin.

Authors:  P W SPEAR
Journal:  Cancer Chemother Rep       Date:  1963-05

2.  Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease.

Authors:  V Parsons; M Baum; M Self
Journal:  Br Med J       Date:  1967-02-25

3.  SERUM ENZYME ACTIVITY DURING RADIOTHERAPY OF MALIGNANT TUMOURS.

Authors:  L R HOLSTI
Journal:  Br J Cancer       Date:  1965-03       Impact factor: 7.640

4.  A trial of mithramycin in the treatment of advanced malignant disease.

Authors:  I A Sewell; H Ellis
Journal:  Br J Cancer       Date:  1966-06       Impact factor: 7.640

  4 in total
  5 in total

1.  Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.

Authors:  Tristan M Sissung; Phoebe A Huang; Ralph J Hauke; Edel M McCrea; Cody J Peer; Roberto H Barbier; Jonathan D Strope; Ariel M Ley; Mary Zhang; Julie A Hong; David Venzon; Jonathan P Jackson; Kenneth R Brouwer; Patrick Grohar; Jon Glod; Brigitte C Widemann; Theo Heller; David S Schrump; William D Figg
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

2.  Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage.

Authors:  Bradley T Scroggins; Jeffrey Burkeen; Ayla O White; Eun Joo Chung; Darmood Wei; Su I Chung; Luca F Valle; Shilpa S Patil; Grace McKay-Corkum; Kathryn E Hudak; W Marston Linehan; Deborah E Citrin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-10-12       Impact factor: 7.038

3.  Letter: Renal function and electrolyte disturbances in normocalcaemic and hypercalcaemic patients treated with mithramycin.

Authors:  J P Fillastre; M A Canonne; C Jeanne; T Bourgeois; J Maitrot; H Gray; P Bastit
Journal:  Br J Cancer       Date:  1974-06       Impact factor: 7.640

Review 4.  Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer.

Authors:  David Schweer; J Robert McCorkle; Jurgen Rohr; Oleg V Tsodikov; Frederick Ueland; Jill Kolesar
Journal:  Biomedicines       Date:  2021-01-12

5.  Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.

Authors:  Jiayin Deng; Ai-Ling Tian; Hui Pan; Allan Sauvat; Marion Leduc; Peng Liu; Liwei Zhao; Shuai Zhang; Hui Chen; Valérie Taly; Pierre Laurent-Puig; Laura Senovilla; Yingqiu Li; Guido Kroemer; Oliver Kepp
Journal:  Cell Death Dis       Date:  2021-10-21       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.